MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
attributable to common...
-$5,430,851
(-14.76%↓ Y/Y)
Net loss
attributable to...
-$74,273
(-151.05%↓ Y/Y)
Net loss
-$5,505,124
(-15.60%↓ Y/Y)
Total operating loss
-$5,294,765
(-16.82%↓ Y/Y)
Total other income
(expense), net
-$210,359
(8.44%↑ Y/Y)
Grant revenue
$336,108
(-45.54%↓ Y/Y)
Total operating
expenses
$5,630,873
(9.35%↑ Y/Y)
Interest expense
-$210,359
(12.01%↑ Y/Y)
General and
administrative
$3,733,597
(18.51%↑ Y/Y)
Research and development
$1,897,276
(-5.09%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)